Xilio Therapeutics (NASDAQ:XLO) Share Price Breaks Above 200-Day Moving Average - What's Next?

Xilio Therapeutics, Inc. (NASDAQ:XLO - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $8.51 and traded as high as $8.85. Xilio Therapeutics shares last traded at $8.68, with a volume of 24,452 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings lowered shares of Xilio Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, October 23rd. Zacks Research upgraded shares of Xilio Therapeutics to a "hold" rating in a report on Thursday, October 22nd. Finally, Raymond James Financial assumed coverage on shares of Xilio Therapeutics in a report on Wednesday, October 21st. They set an "outperform" rating and a $16.00 target price for the company. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $16.00.

Xilio Therapeutics Stock Performance

The business has a fifty day simple moving average of $8.78 and a 200 day simple moving average of $8.51. The stock has a market cap of $57.11 million, a price-to-earnings ratio of -5.29 and a beta of -0.13.

Xilio Therapeutics (NASDAQ:XLO - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.26. The company had revenue of $18.69 million during the quarter, compared to the consensus estimate of $12.72 million. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%. On average, equities research analysts anticipate that Xilio Therapeutics, Inc. will post -3.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Xilio Therapeutics

Several hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC boosted its holdings in shares of Xilio Therapeutics by 252.2% during the second quarter. Stonepine Capital Management LLC now owns 225,994 shares of the company's stock worth $2,165,023 after purchasing an additional 161,832 shares during the last quarter. State Street Corp purchased a new position in Xilio Therapeutics during the second quarter worth approximately $128,000. Finally, BlackRock Inc. purchased a new position in Xilio Therapeutics during the second quarter worth approximately $84,000. 54.29% of the stock is owned by institutional investors and hedge funds.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company's technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects.

Xilio's research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.